{
    "nct_id": "NCT05871970",
    "official_title": "A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations",
    "inclusion_criteria": "* Male or female participants 6 months to less than 18 years of age at the time of informed consent/assent form was signed\n* Participants whose parent/LAR(s) have voluntarily given written consent and participants who provided assent (if applicable) after the study has been explained to them\n* Participants with macrocystic LM or mixed cystic LM (â‰¥ 50% macrocystic disease measured by volume) of the Head/Neck/Mediastinum according to the ISSVA 2018 criteria (ISSVA 2018) measured via LM imaging at Screening to confirm, upon central review, the diagnosis of macrocystic or mixed cystic LM\n* Participants who may have had surgical or sclerotherapy treatment for their LM, but not within six months of the consent/assent form being signed\nHealthy volunteers allowed\nMust have minimum age of 6 Months\nMust have maximum age of 18 Years",
    "exclusion_criteria": "* Penicillin allergy\n* Vascular tumors or combined vascular malformations\n* Microcystic LM or mixed cystic LM with predominant microcystic features\n* LMs of the orbit (orbital LM) as target cyst\n\nFor more information on eligibility criteria, please contact the sponsor.",
    "miscellaneous_criteria": ""
}